ストックスクリーナーアプリを入手
3.13
19.54%
-0.76
アフターアワーズ：
3.12
-0.010
-0.32%
前日終値:
$3.89
開ける：
$3.68
24時間の取引高:
309.49K
Relative Volume:
4.41
時価総額：
$42.05M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-29.82%
1か月 パフォーマンス:
-39.69%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$3.05
$3.68
1週間の範囲:
$3.05
$4.6663
52週間の値動き範囲:
$3.05
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
名前
Onkure Therapeutics Inc
セクター
電話
(720) 307-2892
住所
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
OKUR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
3.13 | 42.05M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-05 | 開始されました | Leerink Partners | Outperform |
| 2024-10-10 | 開始されました | Oppenheimer | Outperform |
| 2023-12-15 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-15 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-12-14 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | 開始されました | William Blair | Outperform |
| 2023-08-28 | 開始されました | H.C. Wainwright | Buy |
| 2023-07-03 | 開始されました | BofA Securities | Buy |
| 2022-09-19 | 再開されました | H.C. Wainwright | Buy |
| 2022-01-27 | 開始されました | Robert W. Baird | Outperform |
| 2021-12-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-22 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-05-04 | 開始されました | Jefferies | Buy |
| 2021-05-04 | 開始されました | Piper Sandler | Overweight |
| 2021-05-04 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Onkure Therapeutics Inc (OKUR) 最新ニュース
OKUR stock touches 52-week low at $3.39 amid market challenges - Investing.com
We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate - simplywall.st
OKUR stock touches 52-week low at $4.43 amid market challenges - Investing.com Australia
OKUR stock touches 52-week low at $4.43 amid market challenges By Investing.com - Investing.com South Africa
Q1 EPS Estimate for OnKure Therapeutics Lowered by Analyst - Defense World
OnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on Thursday - Defense World
H.C. Wainwright cuts OnKure Therapeutics price target to $34 By Investing.com - Investing.com Australia
Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies - TipRanks
H.C. Wainwright cuts OnKure Therapeutics price target to $34 - Investing.com India
Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025 - TipRanks
Analyzing Organogenesis (NASDAQ:ORGO) and OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OKUR stock touches 52-week low at $4.54 amid market challenges - Investing.com Australia
Onkure discovers new PI3Kα inhibitors - BioWorld Online
What is Lifesci Capital’s Estimate for OKUR FY2025 Earnings? - Defense World
Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects - TipRanks
Will OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely? - Yahoo Finance
OnKure Therapeutics (NASDAQ:OKUR) Given New $30.00 Price Target at Oppenheimer - Defense World
OnKure Therapeutics Reports Progress and Financials - TipRanks
OnKure boosts R&D spending with cancer trial underway - BizWest
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Oppenheimer Adjusts Price Target on OnKure Therapeutics to $30 From $35, Keeps Outperform Rating - Marketscreener.com
OnKure Therapeutics price target lowered to $30 from $35 at Oppenheimer - TipRanks
OnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c) - TipRanks
OnKure Therapeutics, Inc. SEC 10-K Report - TradingView
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
OnKure Therapeutics Inc. (OKUR) reports earnings - Quartz
OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences - GlobeNewswire
OnKure Therapeutics (NASDAQ:OKUR) Trading Down 4.7% – Time to Sell? - Defense World
FY2025 Earnings Estimate for OKUR Issued By Leerink Partnrs - Defense World
Vanguard Group Inc's Strategic Acquisition of OnKure Therapeutics Shares - GuruFocus.com
After A Clear Safety Picture, OnKure Prepares For Pivotal PIKture-01 Data On OKI-219 - RTTNews
Jones Trading Initiates Coverage of OnKure Therapeutics (OKUR) with Buy Recommendation - Nasdaq
Jones Trading sets OnKure stock Buy rating, $32 target - MSN
Jones Trading sets OnKure stock Buy rating, $32 target By Investing.com - Investing.com South Africa
OnKure Therapeutics (NASDAQ:OKUR) Trading Down 3.4% – Here’s Why - Defense World
Reneo Pharmaceuticals stock hits 52-week low at $5.66 By Investing.com - Investing.com Australia
Reneo Pharmaceuticals stock hits 52-week low at $5.66 - Investing.com India
Reneo Pharmaceuticals stock hits 52-week low at $7.64 By Investing.com - Investing.com Australia
Reneo Pharmaceuticals stock hits 52-week low at $7.64 - Investing.com India
OnKure Therapeutics (NASDAQ:OKUR) Trading 4% Higher – Time to Buy? - Defense World
Reneo Pharmaceuticals stock hits 52-week low at $7.91 By Investing.com - Investing.com Nigeria
Reneo Pharmaceuticals stock hits 52-week low at $7.91 - Investing.com India
OKUR Stock Hits 52-Week Low at $10.51 Amid Market Challenges - Investing.com Australia
Onkure Therapeutics Inc (OKUR) 財務データ
Onkure Therapeutics Inc (OKUR) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):